COPENHAGEN, Sept 14 (Reuters) - Danish biotech company Genmab A/S will collaborate in cancer drug research with Seattle Genetics under a strategy to focus on strategic partnerships for drug ...

A month has gone by since the last earnings report for Seattle Genetics . Shares have added about 24.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2017. The company also highlighted ADCETRIS ...

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ: SGEN) today announced dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SGN-CD48A for ...

Fintel reports that Capital International Investors has filed a 13G/A form with the SEC disclosing ownership of 18.06MM shares of Seattle Genetics, Inc. (SGEN). This represents 9.7% of the company. In ...

Seattle Genetics (SGEN) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.74 per share a year ago. These figures are ...

LOS ANGELES, Sept 24 (Reuters) - Biotechnology company Seattle Genetics will announce on Monday results from a pivotal trial of experimental drug brentuximab vedotin in patients with Hodgkin lymphoma.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Drug development partner Takeda is paying Seattle Genetics ...

Sales of Adcetris in the U.S. and Canada jumped 30% year over year as the drug continues to make gains in treating peripheral T-cell lymphoma as well as frontline Hodgkin lymphoma. Royalty revenue, ...

Clay Siegall is the founder and CEO of Seattle Genetics. Anthony Bolante | PSBJ To continue reading this content, please enable JavaScript in your browser settings ...